Lost Coverage for Zepbound or Wegovy? 5 Options in 2026

• Prior-authorization denial: the drug is on your plan, but you did not meet its criteria (BMI thresholds, documented conditions, a prior program). Your prescriber can often appeal with stronger documentation.
• Formulary exclusion: your plan no longer covers the drug for weight management at all. No appeal fixes that; you need another route.
• A plan change at work or at the new year: treat it as an exclusion until shown otherwise.

Sometimes. Both manufacturers sell direct and publish prices.

The clearest current example is Eli Lilly's Foundayo (orforglipron), the daily pill FDA-approved in April 2026. Through LillyDirect it lists $149 a month at the 0.8 mg starting dose, $199 at 2.5 mg, $299 at 5.5 and 9 mg, and $349 at 14.5 and 17.2 mg, or $25 a month for commercially insured patients using its savings card, which can apply even when the plan itself refuses to pay.

Zepbound and Wegovy also have savings cards with their own eligibility rules; we have not verified their current terms, so check each manufacturer's page. Buying direct still requires a prescription from a licensed clinician.

Possibly, through the biggest change of 2026 for Medicare beneficiaries. The Medicare GLP-1 Bridge is a CMS pilot that runs from July 1, 2026 through December 31, 2027.

Eligible beneficiaries pay a flat $50 copay at the pharmacy for covered obesity drugs: the Wegovy pill and injection, the Zepbound KwikPen and Foundayo. The copay stays at $50 as the dose rises.

Eligibility depends on clinical criteria and an approval step, and the program is explicitly temporary. Our GLP-1s after 65 page covers what we could verify and what to ask CMS or your Part D plan.

• altRx: Zepbound $1,249 a month, Wegovy $1,579
• welludr: Zepbound $1,599
• Sprout: Wegovy $1,799
• ro: Zepbound KwikPen from $299 for the first month, then $399-449, plus a membership. Because ro bills the pen as its own line item, a plan that still covers it can pay its share.

• A compounded product has the same active ingredient but is prepared by a pharmacy rather than manufactured as an approved drug.
• It has no clinical trials of its own.
• Insurance never covers it.
• The FDA sent warning letters to dozens of telehealth companies in 2026 over how these products are marketed.

Not necessarily. Restarting at the lowest dose after months of titration is the biggest worry for most people, but it is a clinical decision, not a provider policy.

A licensed clinician at the new provider reviews your current dose and history, then decides whether to continue at that dose or step down; most telehealth intake forms ask for it. Bring your current prescription and the date of your last injection.

Practical steps, including timing the switch so you do not run out, what to send and what to ask, are in switching from Ozempic or another GLP-1. Do not fill the gap with an unregulated "research peptide" bought without a prescription; here is why.

1. Appeal, if the drug is still on your formulary.
2. Check the manufacturer's savings card and direct price.
3. If you are on Medicare, apply for the $50 Bridge.
4. Choose between brand-name cash and a compounded switch, based on your budget and how you weigh the trade-offs.